BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
BioStem Technologies Inc. (OTC PINK: BSEM) announced that CEO Jason Matuszewski will present at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, from 1:30-1:55 PM EDT. The event will take place in the Preserve Ballroom B. Management will also hold one-on-one meetings with investors throughout the conference. A live webcast of the presentation will be available, along with an archived recording accessible for 90 days on the company’s website. BioStem focuses on regenerative medicine, particularly placental-derived tissue allografts.
- None.
- None.
POMPANO BEACH, FLORIDA., Oct. 10, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC PINK: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived tissue allografts, today announced that Jason Matuszewski, Chief Executive Officer, will present at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12th, 2022. Company management will also meet with investors in 1x1 meetings throughout the conference. To schedule a meeting with management, please contact your Dawson James representative.
Dawson James Securities 2022 Small Cap Growth Conference
When: Wednesday, October 12, 2022 from 1:30-1:55PM EDT
Location: Track 2 – Preserve Ballroom B
Webcast: Dawson James Securities Conference Webcast Link
A live webcast of the presentation will be available at the above webcast link. An archived recording of BioStem’s presentation at the conference will be available under the Investor Relations portion of the Company's website and will be available for 90 days.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJETM, VENDAJETM AC, and VENDAJETM OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.
Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
Investor Relations:
Russo Partners, LLC
Maxim Jacobs, CFA
12 West 27th Street, 4th Floor
New York, NY 10001
T: 646-942-5591
Maxim.Jacobs@russopartnersllc.com
FAQ
When is the Dawson James Securities 2022 Small Cap Growth Conference for BSEM?
Who will present at the Dawson James Securities Conference for BSEM?
Where is the Dawson James Securities Conference taking place for BSEM?
Will there be a webcast for BSEM's presentation at the conference?
How long will the recording of BSEM's presentation be available?
What products does BioStem Technologies focus on?
